Literature DB >> 6149761

Severe systemic vascular necrosis in cyclosporin-treated rabbits with acute serum sickness.

G H Neild, K Ivory, D G Williams.   

Abstract

Rabbits given acute serum sickness (ASS) and treated with cyclosporin A (CyA) developed a severe, systemic vascular injury, which was not similar to that normally seen in ASS. Thirty-three NZW rabbits received a single intravenous injection of 250 mg/kg bovine serum albumen (BSA) with or without endotoxin (5 micrograms/kg), on day 0. Groups of rabbits were given intramuscular CyA as follows: 15 mg/kg/day from day -2 to +8, or 25 mg/kg/day from day -2 to +3 or day 0 to 5. Muscular arteries of the heart and splanchnic organs developed an arterial injury in which there was extensive fibrinoid necrosis of the vessel wall but little or none of the mononuclear cell reaction that is normally associated with the arteritis of ASS. A microvascular injury also occurred which led to interstitial haemorrhage in the gastric mucosa and multi-focal necrosis in the heart and liver. These lesions were seen with equal frequency in all groups of rabbits with serum sickness who received CyA, irrespective of whether they also received endotoxin. We suggest that CyA altered the host inflammatory response to the injury initiated by the BSA-anti-BSA immune complexes and this led to enhanced vascular injury. The inhibition by CyA of the perivascular cellular reaction suggests that this reaction may be mediated by T lymphocytes. This model should provide further insight into the pathogenesis of arteritis, as well as the mechanisms of cyclosporin toxicity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149761      PMCID: PMC2040997     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  15 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  Morphologic changes in rabbits following the intravenous administration of meningococcal toxin. I. The effects produced in young and in mature animals by a single injection.

Authors:  J G BRUNSON; C N GAMBLE; L THOMAS
Journal:  Am J Pathol       Date:  1955 May-Jun       Impact factor: 4.307

3.  Intravascular platelet clumping in rabbits.

Authors:  A HUGHES; R S TONKS
Journal:  J Pathol Bacteriol       Date:  1962-10

Review 4.  Immune complex disease in experimental animals and man.

Authors:  C G Cochrane; D Koffler
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

5.  Yogurt--an autodigesting source of lactose.

Authors:  J C Kolars; M D Levitt; M Aouji; D A Savaiano
Journal:  N Engl J Med       Date:  1984-01-05       Impact factor: 91.245

6.  Cyclosporine and human neutrophil function.

Authors:  R L Janco; D English
Journal:  Transplantation       Date:  1983-05       Impact factor: 4.939

7.  Effects of the new anti-lymphocytic peptide cyclosporin A in animals.

Authors:  J F Borel; C Feurer; C Magnée; H Stähelin
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

8.  Accelerated serum sickness in the rabbit. IV. Characteristic endarteritis in the pulmonary artery.

Authors:  Y Kondo; Y Niwa; J Takizawa; B Akikusa; M Sano; H Shigematsu
Journal:  Lab Invest       Date:  1979-08       Impact factor: 5.662

9.  Glomerular thrombosis and cortical infarction in cyclosporin-treated rabbits with acute serum sickness.

Authors:  G H Neild; K Ivory; D G Williams
Journal:  Br J Exp Pathol       Date:  1984-02

10.  Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes.

Authors:  K Atkinson; J C Biggs; J Hayes; M Ralston; A J Dodds; A J Concannon; D Naidoo
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

View more
  3 in total

Review 1.  Lessons from animal models of vasculitis.

Authors:  I G Luzina; B S Handwerger
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 3.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.